EPs 7630 in Acute Respiratory Tract Infections – A systematic Review and Meta-Analysis of Randomized Clinical Trials

Clinical Efficacy and Safety of Liquid Pelargonium sidoides Preparation (EPs 7630) in Children with Acute Non-Streptococcal Tonsillopharyngitis

“…Moreover, a meta-analysis of data from an earlier published clinical trial, and the independently obtained results of the trial presented here (22) shows an overall pattern of expedited treatment effect onset and shortened disease duration under EPs 7630 as compared to placebo. This finding could be based on the particular mode of action in EPs 7630, which comprises of antiviral (6-8), antibacterial (9) and immune modulating effects (9)(10)(11).…”

“…The outcome measure employed in the trials investigating EPs 7630 in acute bronchitis, the bronchitis severity scale (BSS), comprises of five symptoms indicative of acute bronchitis, namely coughing, sputum production, rales/rhonchi at auscultation, chest pain during coughing, and dyspnea, and is a reliable tool for assessing actual symptom severities in acute bronchitis. A recently published meta-analysis evaluating the results of randomized clinical trials investigating EPs 7630 in acute bronchitis and other RTI stated the superiority of EPs 7630 to placebo in reducing the BSS total score over a treatment duration of 7 days (22).…”

Faster recovery and reduced paracetamol use – a meta-analysis of EPs 7630 in children with acute respiratory tract infections

“…EPs 7630 1 is an extract from the roots of Pelargonium sidoides. In acute respiratory infections such as ATP and AB, randomised, placebo-controlled trials have confirmed the symptom alleviating effect of EPs 7630 [31][32][33][34][35], while a comprehensive safety review based on more than 8000 patients exposed to EPs 7630 showed adverse event rates similar to those observed for placebo [36]. Pharmacological studies indicate that the clinical effects of EPs 7630 are closely related to its antiviral and antibacterial action.…”

Evaluation of pharmacodynamic activities of EPs® 7630, a special extract from roots of Pelargonium sidoides, in animals models of cough, secretolytic activity and acute bronchitis

“…for the indication "acute bronchitis" by the German Federal Institute for Drugs and Medical Devices in 2005 (Brendler 2008). Therapeutic efficacy in this and related indications such as common cold, rhinosinusitis, tonsillopharyngitis, and chronic obstructive pulmonary disease has been evaluated in numerous randomized, double-blind and placebo-controlled trials as well as observational clinical study in patients from an age of one year upwards (Moyo and Van Staden 2014;Matthys et al 2014). Safety and tolerability of EPs R 7630 has been demonstrated in 29 clinical trials and post-marketing surveillance studies involving more than 10,000 adults and children (Matthys et al 2013).…”